Abstract
Tetherin is a type II membrane protein that bears a N-terminal transmembrane domain, an extracellular coiledcoil structure and a C-terminal GPI anchor. This unique topology allows tetherin to block the release of a wide range of enveloped viruses from the cell surface. In order to overcome this host restriction, viruses have evolved various counter measures. In the case of human immunodeficiency virus type 1 (HIV-1), the viral protein U (Vpu) is able to downmodulate cell surface tetherin, thus removing tetherin molecules from the site of virus budding. This activity of Vpu depends on its direct interaction with tetherin. In this review, we summarize the known molecular details of the interaction between Vpu and tetherin, and also discuss how tetherin is targeted by other viral antagonists. Following our summary, it is evident that each of the intracellular, transmembrane and extracellular domains of tetherin can become the target of viral antagonists for counteraction.
Keywords: HIV, Vpu, tetherin, Nef, Envelope, CD4, transmembrane domain, NMR, TM, residues
Current HIV Research
Title:Transmembrane Interactions of HIV-1 Vpu and Tetherin
Volume: 10 Issue: 4
Author(s): Fei Guo and Chen Liang
Affiliation:
Keywords: HIV, Vpu, tetherin, Nef, Envelope, CD4, transmembrane domain, NMR, TM, residues
Abstract: Tetherin is a type II membrane protein that bears a N-terminal transmembrane domain, an extracellular coiledcoil structure and a C-terminal GPI anchor. This unique topology allows tetherin to block the release of a wide range of enveloped viruses from the cell surface. In order to overcome this host restriction, viruses have evolved various counter measures. In the case of human immunodeficiency virus type 1 (HIV-1), the viral protein U (Vpu) is able to downmodulate cell surface tetherin, thus removing tetherin molecules from the site of virus budding. This activity of Vpu depends on its direct interaction with tetherin. In this review, we summarize the known molecular details of the interaction between Vpu and tetherin, and also discuss how tetherin is targeted by other viral antagonists. Following our summary, it is evident that each of the intracellular, transmembrane and extracellular domains of tetherin can become the target of viral antagonists for counteraction.
Export Options
About this article
Cite this article as:
Guo Fei and Liang Chen, Transmembrane Interactions of HIV-1 Vpu and Tetherin, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792450
DOI https://dx.doi.org/10.2174/157016212800792450 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets Potential and Cytotoxicity of cis-Platinum Complex with Anti-tumor Activity in Combination Therapy
Recent Patents on Anti-Cancer Drug Discovery Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Chemical and Structural Diversity of siRNA Molecules
Current Topics in Medicinal Chemistry Dihydroresveratrol Type Dihydrostilbenoids: Chemical Diversity, Chemosystematics, and Bioactivity
Current Medicinal Chemistry Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation
Current Stem Cell Research & Therapy c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Role of the Mannose Receptor in the Immune Response
Current Molecular Medicine Circadian Timekeeping in Anticancer Therapeutics: An Emerging Vista of Chronopharmacology Research
Current Drug Metabolism Radiolabeled Nucleoside Analogues for PET Imaging of HSV1-tk Gene Expression
Current Topics in Medicinal Chemistry Expression and Characterisation of Recombinant Molecules in Transgenic Soybean
Current Pharmaceutical Design Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Innate Immunity and Intracellular Trafficking: Insights for Novel Anti- HIV-1 Therapeutics
Current Pharmacogenomics Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry A Novel Hydroxysteroid-Sulfating Cytosolic Sulfotransferase, SULT3 ST3, from Zebrafish: Identification, Characterization, and Ontogenic Study
Drug Metabolism Letters Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic Thiol Alkylators
Mini-Reviews in Medicinal Chemistry